MedTrace Logo

Efficacy and Safety of Jinhua Qinggan Granules (JHQG) for the Use of Acute Upper Respiratory Infection

NCT07720583 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 546

Last updated 2026-07-28

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if drug Jinhua Qinggan Granules (JHQG) works to treat acute upper respiratory tract infection in adults. It will also learn about the safety of drug JHQG. The main questions it aims to answer is:

• Following three days of treatment, the overall grade of fever, sore throat, nasal congestion, rhinorrhea, headache, sneezing, cough, and malaise dropped to zero for a whole day.

Researchers will compare drug JHQG to a placebo (a look-alike substance that contains no drug) to see if drug JHQG works to treat acute upper respiratory tract infection.

Participants will:

* Take drug JHQG or a placebo 3 times daily for 3 days
* All subjects are followed up before the trial, and on the same day or day after completing 3 days of medication.

Conditions

  • Acute Rhinitis
  • Acute Pharyngitis
  • Acute Tonsillitis
  • Acute Sinusitis

Interventions

DRUG

Jinhua Qinggan Granules

Jinhua Qinggan Granules administered orally according to the study protocol.

DRUG

Placebo

Placebo granules matched in appearance and administration to Jinhua Qinggan Granules.

Sponsors & Collaborators

  • Juxiechang (Beijing) Pharmaceuticals Co., Ltd. Beijing, China.

    collaborator UNKNOWN

  • University of Karachi

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-24
Primary Completion
2026-04-24
Completion
2026-04-27

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07720583 on ClinicalTrials.gov